# AngioDynamics, Inc. (ANGO) Stock Analysis: Exploring a 92% Potential Upside in the Medical Technology Sector

- Link: https://www.directorstalkinterviews.com/angiodynamics-inc-ango-stock-analysis-exploring-a-92-potential-upside-in-the-medical-technology-sector/4121234273
- Published: 2026-01-09T11:37:10+00:00
- Author: Madison Wilson

AngioDynamics, Inc. (NASDAQ: ANGO), a notable player in the healthcare sector, has
caught the attention of investors, not least because of its potential upside of 
over 92%, as per analyst ratings. With its current price standing at $10.05 and 
a market cap of $414.23 million, the company offers an intriguing proposition in
the medical instruments and supplies industry.

AngioDynamics is renowned for its innovative medical technology solutions, including
devices for treating peripheral vascular disease and products for oncology and surgical
settings. Its flagship offerings, such as the Auryon Atherectomy system and AlphaVac
mechanical thrombectomy system, highlight the company’s commitment to advancing 
medical procedures and improving patient outcomes.

Despite its potential, AngioDynamics presents a mixed bag in terms of financial 
health. The company’s forward P/E ratio stands at a concerning -91.36, signaling
potential challenges in profitability. Moreover, its EPS is at -0.67, and the return
on equity is -15.26%, indicating inefficiencies in generating returns from shareholder
investments.

On the performance front, AngioDynamics has demonstrated a commendable revenue growth
of 9%, which is a positive sign of its ability to capture market share and expand
its footprint in the competitive medical technology landscape. However, the absence
of net income figures and dividend payouts may pose concerns for income-focused 
investors.

From a technical analysis perspective, the stock’s 50-day moving average is at 12.57,
below its 200-day moving average of 10.61, suggesting a bearish trend. The Relative
Strength Index (RSI) of 40.75 indicates that the stock is nearing oversold territory,
which might present a buying opportunity for contrarian investors.

Analyst ratings paint a promising picture, with three buy ratings and no hold or
sell recommendations. The target price range of $16.00 to $24.00, with an average
target of $19.33, underscores the confidence that analysts have in AngioDynamics’
growth potential. This optimistic outlook is bolstered by the company’s strategic
focus on cutting-edge medical technologies and its diverse product portfolio, which
includes the innovative NanoKnife IRE Ablation System and the Solero Microwave Tissue
Ablation System.

For investors considering AngioDynamics, the key lies in balancing the high potential
upside against the financial challenges. The company’s ability to navigate its profitability
issues while capitalizing on its growth opportunities will be crucial in realizing
the projected valuations.

In the competitive landscape of medical technology, AngioDynamics’ focus on innovation
and expansion could offer significant returns for investors willing to embrace some
risk. As the company continues to refine its product offerings and enhance operational
efficiencies, it stands well-positioned to capitalize on the growing demand for 
advanced medical solutions in the United States and beyond.

Share on: